Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

IGF-I levels in patients with type 1 diabetes without endogenous insulin production are low.

Their aim was to examine whether the plasma insulin profile obtained by treatment with the insulin analogue lispro has a different effect on plasma concentrations of IGF-I and IGFBP-1 than that seen during treatment with conventional human insulin (regular insulin).

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Twelve patients with type 1 diabetes, age 47.8 +/- 2.4 years (mean +/- SEM), body mass index 26.5 +/- 1.0 kg/m2, diabetes duration 30.5 +/- 3.2 years participated in this open label randomized cross-over study.

How the Study Was Run

The design is described as randomized, open-label and crossover.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Insulin Lispro was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

In the crossover set-up each of the participants took both Insulin Lispro and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Insulin Lispro, Insulin-Like Growth Factor Binding Protein 1 and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Clinical endocrinology), a journal based in England.

More context: the Insulin Lispro compound page, all human trials.